Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Cirone, Mara ^a   Garufi, Alessia ^b   Di Renzo, Livia ^a   Granato, Marisa ^a   Faggioni, Alberto ^a   D'Orazi, Gabriella ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Apoptosis; Calreticulin; Chemoresistance; Chemotherapy; Combination therapy; Dendritic cell activation; Immunogenicity; p53 reactivation; Tumor cells; ZnCl2

Indexed keywords

CALRETICULIN; CD83 ANTIGEN; CD86 ANTIGEN; CISPLATIN; DOXORUBICIN; INITIATION FACTOR 2ALPHA; PROTEIN P53; UNCLASSIFIED DRUG; ZINC DERIVATIVE; ZINC DICHLORIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL ACTIVATION; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; UPREGULATION;

EID: 84885956128     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26198     Document Type: Article

References (35)

1. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/ onci.23510
2. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73; PMID:19935675; http://dx.doi.org/10.1038/nrc2763
3. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26:2243-54; PMID:17401433; http://dx.doi.org/10.1038/sj.onc.1210295
4. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, et al. Reversible dysfunction of wildtype p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 2008; 68:3707-14; PMID:18483253; http://dx.doi.org/10.1158/0008- 5472.CAN-07-6776
5. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One 2009; 4:e6819; PMID:19714248; http://dx.doi. org/10.1371/journal.pone.0006819
6. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D'Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10:1679-89; PMID:21508668; http:// dx.doi.org/10.4161/cc.10.10.15642
7. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 2012; 131:E562- 8; PMID:21932419; http://dx.doi.org/10.1002/ ijc.26441
8. Zitvogel L, Casares N, Péquignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84:131- 79; PMID:15246252; http://dx.doi.org/10.1016/ S0065-2776(04)84004-5
9. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146-52; PMID:20970973; http://dx.doi.org/10.1016/j.coi.2010.09.008
10. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http:// dx.doi.org/10.1038/nm1523
11. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; http://dx.doi. org/10.1038/emboj.2011.497
12. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of preapoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1
13. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 2012; 7:e31732; PMID:22412839; http:// dx.doi.org/10.1371/journal.pone.0031732
14. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218-9; PMID:23170286; http://dx.doi.org/10.4161/onci.20428
15. Biroccio A, Bufalo DD, Ricca A, D'Angelo C, D'Orazi G, Sacchi A, Soddu S, Zupi G. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther 1999; 6:1064-72; PMID:10455409; http:// dx.doi.org/10.1038/sj.gt.3300935
16. D'Avenia P, Porrello A, Berardo M, Angelo MD, Soddu S, Arcangeli G, Sacchi A, D'Orazi G. Tp53- gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett 2006; 231:102-12; PMID:16356835; http://dx.doi.org/10.1016/j.canlet.2005.01.033
17. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733-7; PMID:10481009; http://dx.doi. org/10.1126/science.285.5434.1733
18. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191:411- 6; PMID:10662786; http://dx.doi.org/10.1084/ jem.191.3.411
19. Blachère NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005; 3:e185; PMID:15839733; http://dx.doi.org/10.1371/journal. pbio.0030185
20. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100-4; PMID:20421432; http://dx.doi.org/10.1158/1078- 0432.CCR-09-2891
21. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, Klausner RD. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 1989; 56:801-13; PMID:2647301; http://dx.doi. org/10.1016/0092-8674(89)90685-5
22. Zhang K, Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004; 279:25935-8; PMID:15070890; http://dx.doi.org/10.1074/jbc.R400008200
23. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499-509; PMID:18464797; http://dx.doi.org/10.1038/cdd.2008.67
24. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8:413-5; PMID:22361584; http://dx.doi.org/10.4161/ auto.19009
25. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2013; [Epub ahead of print]; PMID:23686135; http:// dx.doi.org/10.1038/cdd.2013.48
26. Beyersmann D, Haase H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 2001; 14:331-41; PMID:11831463; http:// dx.doi.org/10.1023/A:1012905406548
27. Hainaut P, Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res 1993; 53:1739- 42; PMID:8467489
28. Méplan C, Richard M-J, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000; 19:5227- 36; PMID:11077439; http://dx.doi.org/10.1038/ sj.onc.1203907
29. Petersen TR, Dickgreber N, Hermans IF. Tumor antigen presentation by dendritic cells. Crit Rev Immunol 2010; 30:345-86; PMID:20666707; http://dx.doi.org/10.1615/CritRevImmunol.v30. i4.30
30. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3-12; PMID:18007663; http://dx.doi.org/10.1038/sj.cdd.4402269
31. Cirone M, Lucania G, Aleandri S, Borgia G, Trivedi P, Cuomo L, Frati L, Faggioni A. Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells. Immunol Lett 2008; 120:37-41; PMID:18680763; http://dx.doi.org/10.1016/j.imlet.2008.06.011
32. Cirone M, Di Renzo L, Trivedi P, Lucania G, Borgia G, Frati L, Faggioni A. Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK. Int J Immunopathol Pharmacol 2010; 23:1079-86; PMID:21244757
33. Garufi A, Pistritto G, Ceci C, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D'Orazi G. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One 2012; 7:e48342; PMID:23144866; http://dx.doi.org/10.1371/journal.pone.0048342
34. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004; 293:311-20; PMID:14729469; http://dx.doi. org/10.1016/j.yexcr.2003.09.032
35. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D'Orazi G. Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med 2010; 48:1338-46; PMID:20171273; http://dx.doi. org/10.1016/j.freeradbiomed.2010.02.015